HIF2 Inhibitor Joins the Kidney Cancer Armamentarium

[1] HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (34) : 14391 - 14396

[2] Targeting renal cell carcinoma with a HIF-2 antagonist [J]. NATURE, 2016, 539 (7627) : 112 - +

[3] On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models [J]. NATURE, 2016, 539 (7627) : 107 - +

[4] Systemic Therapy for Metastatic Renal-Cell Carcinoma [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) : 354 - 366

[5] Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 867 - +

[6] Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing [J]. NATURE GENETICS, 2014, 46 (03) : 225 - +

[7] Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) : 883 - 892

[8] HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma [J]. CANCER CELL, 2008, 14 (06) : 435 - 446

[9] Kaelin W, 2015, MOL BIOL KIDNEY CANC, P31

[10] The concept of synthetic lethality in the context of anticancer therapy [J]. NATURE REVIEWS CANCER, 2005, 5 (09) : 689 - 698

[1] HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (34) : 14391 - 14396

[2] Targeting renal cell carcinoma with a HIF-2 antagonist [J]. NATURE, 2016, 539 (7627) : 112 - +

[3] On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models [J]. NATURE, 2016, 539 (7627) : 107 - +

[4] Systemic Therapy for Metastatic Renal-Cell Carcinoma [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) : 354 - 366

[5] Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 867 - +

[6] Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing [J]. NATURE GENETICS, 2014, 46 (03) : 225 - +

[7] Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10) : 883 - 892

[8] HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma [J]. CANCER CELL, 2008, 14 (06) : 435 - 446

[9] Kaelin W, 2015, MOL BIOL KIDNEY CANC, P31

[10] The concept of synthetic lethality in the context of anticancer therapy [J]. NATURE REVIEWS CANCER, 2005, 5 (09) : 689 - 698